You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

YUTOPAR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Yutopar, and when can generic versions of Yutopar launch?

Yutopar is a drug marketed by Astrazeneca and is included in two NDAs.

The generic ingredient in YUTOPAR is ritodrine hydrochloride. There are five drug master file entries for this compound. Additional details are available on the ritodrine hydrochloride profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for YUTOPAR?
  • What are the global sales for YUTOPAR?
  • What is Average Wholesale Price for YUTOPAR?
Summary for YUTOPAR
Drug patent expirations by year for YUTOPAR
Recent Clinical Trials for YUTOPAR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Cairo UniversityPhase 4

See all YUTOPAR clinical trials

US Patents and Regulatory Information for YUTOPAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca YUTOPAR ritodrine hydrochloride INJECTABLE;INJECTION 018580-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Astrazeneca YUTOPAR ritodrine hydrochloride INJECTABLE;INJECTION 018580-002 Sep 27, 1984 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Astrazeneca YUTOPAR ritodrine hydrochloride TABLET;ORAL 018555-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for YUTOPAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca YUTOPAR ritodrine hydrochloride INJECTABLE;INJECTION 018580-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Astrazeneca YUTOPAR ritodrine hydrochloride TABLET;ORAL 018555-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Astrazeneca YUTOPAR ritodrine hydrochloride INJECTABLE;INJECTION 018580-002 Sep 27, 1984 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for YUTOPAR

See the table below for patents covering YUTOPAR around the world.

Country Patent Number Title Estimated Expiration
France 1483718 Nouvelle aralkylamine et sa prĂ©paration ⤷  Sign Up
United Kingdom 1111451 ⤷  Sign Up
Switzerland 539604 Verfahren zur Herstellung eines sekundären Aralkylamins und dessen Salze ⤷  Sign Up
Denmark 116740 ⤷  Sign Up
Spain 309809 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.